secwatch / observer
8-K filed August 11, 2021, 7:59 PM ET ticker VSBC CIK 0001697884
leadership confidence high sentiment neutral materiality 0.60

CEO Chu Pao-Chi resigns; Kao Cheng-Hsiang appointed CEO and retains Secretary role

VITASPRING BIOMEDICAL CO. LTD.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kao Cheng-Hsiang

Chief Executive Officer
VITASPRING BIOMEDICAL CO. LTD.
Effective
2020-08-07
Filed
August 11, 2021, 7:59 PM ET
current secretary of the Company, Kao Cheng-Hsiang, was appointed CEO and retains his position as Secretary.
Role change

Chu Pao-Chi

Chief Executive Officer
VITASPRING BIOMEDICAL CO. LTD.
Effective
2020-08-07
Successor
Kao Cheng-Hsiang
Filed
August 11, 2021, 7:59 PM ET
Effective August 7, 2020, Chu Pao-Chi Chairman of the Board of Directors, and Chief Executive Officer of the Company, resigned his position as CEO

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kao Cheng-Hsiang was appointed as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
current secretary of the Company, Kao Cheng-Hsiang, was appointed CEO and retains his position as Secretary.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Chu Pao-Chi resigned as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..

Action
resigned
Role
Chief Executive Officer
Exact text from the filing
Effective August 7, 2020, Chu Pao-Chi Chairman of the Board of Directors, and Chief Executive Officer of the Company, resigned his position as CEO
View on SEC.gov

VITASPRING BIOMEDICAL CO. LTD. filing history →

Source: SEC EDGAR
accession 0001697884-21-000011
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.